|
||
Brief Definitive Reports |
| Abstract |
|---|
|
|
|---|
after in vitro stimulation with carrier antigen KLH. In contrast, priming of T helper cells and Ig class switch are normal in mice deficient with either HSA or CD28 alone. IgM responses are not affected by any of these targeted mutations. These results demonstrate that CD28-independent induction of T helper cells and Ig class-switches requires costimulation by the HSA.
Immunological help from T cells to B cells is essential for the induction of antibody class switching and B cell memory. Since induction of T cell help requires costimulation by the antigen-presenting cells (1), lack of proper costimulation leads to defective T cell–dependent antibody response (2, 3). For some antigens (2, 4), substantial defects in Ig class switches and memory of T cell–dependent antibody responses have been reported in mice with a targeted mutation of CD28 gene that encodes for a major receptor for B7 family of costimulatory molecules (5). Interestingly, the extent of defects varies depending on the types of antigens used. For instance, IgG responses to NIP (hydroxy-iodo-nitrophenyl-acetyl)–coupled chicken gamma globulin and goat anti–mouse IgD are severely reduced in CD28-deficient mice (2, 4), whereas blockade of B7-CD28/ CTLA4 interaction only marginally affects IgG responses in mice infected with viruses such as lymphocytic choriomeningitis virus (LCMV) (6, 7) and vesicular stomatitis (VSV) (7), or a nematode parasite, Heligmosomoides polygyrus (4).
Two hypotheses can be invoked to explain the CD28-independent IgG responses. First, T cells specific for the antigens can be activated by TCR ligand in the absence of costimulation. Second, activation of T cells specific for these antigens requires costimulation provided by other costimulatory molecules. Recent studies from several laboratories including ours have demonstrated that multiple costimulatory molecules, such as the heat-stable antigen (HSA; references 8–13), CD48 (14, 15), CD44H (16), intercellular adhesion molecule 1 (ICAM-1; references 17, 18), and 4-1BB ligand (19, 20) can promote T cell activation in a number of experimental models. It is therefore plausible that these costimulators may compensate for the CD28-deficiency. We are especially interested in the role of HSA in CD28-deficient mice, as we and others have established that this molecule plays a critical role in the induction of T cell clonal expansion (8–10), CTL maturation (10–12), and induction of CD8 T cell memory (12, 13). To test whether CD28-independent induction of immunological help for CD4 T cells requires costimulation by HSA, we compared activation of T helper cells as well as T-dependent antibody responses in wild-type mice to those in mice that are deficient of CD28 alone, HSA alone, and both HSA and CD28. Our results demonstrated that after immunization with DNP-coupled KLH, mice deficient for both HSA and CD28 failed to produce DNP-specific IgG1, IgG2a, IgG2b, IgG3, and IgA. This deficiency correlates with a defective induction of antigen-specific cytokine-producing cells. In contrast, substantial IgG1, IgG2a, and IgG2b responses and cytokine-producing cells are present in mice that are deficient for either CD28 or HSA. Thus, CD28-independent induction of T helper function and Ig class switches require costimulation by the HSA.
Immunization and Measurement of DNP-specific Antibody Responses.
![]()
Materials and Methods
Top
Abstract
Materials and Methods
Results and Discussion
References
Experimental Animals.
Mice deficient for CD28 gene (6) were provided by Dr. Tak Mak (University of Toronto, Toronto, Ontario, Canada); those deficient for HSA (21) were a gift from Dr. Peter Nielsen (Max Planck Institut fur Immunologie, Freiburg, Germany), and those deficient for both HSA and CD28 were produced as previously described (12). CD28-deficient mice have been backcrossed to C57BL6/j for six generations, while the HSA-deficient mice were produced using ES cells from C57BL6/j mice, as described. C57BL6/j mice purchased from the National Cancer Institute (Rockville, MD) were used as controls. Mice between 6 and 16 wk of age were used for the study.
Age- and sex-matched mice were immunized intraperitoneally with 50 µg/mouse of DNP-KLH (Sigma Chemical Co., St. Louis, MO) in CFA. Sera were collected at day 7 after the primary immunization. The immunized mice were boosted with 50 µg of KLH-DNP in IFA at 2 wk after the primary immunization, and the sera were collected at 2 wk after the second immunization, as indicated in Fig. 1. 1 mo after the second immunization, mice were killed and the spleen cells were harvested for ELISA spot assay (Fig. 1).
|
ELISA Spot Assay to Detect Cytokine-producing Cells.
We used antibody pairs from PharMingen to detect cytokine-producing cells using MultiscreenTM 96-well filtration plates (MAHA S45 10; Millipore, France). In brief, the filtration plates were coated with purified mAbs specific for either IL-2 (JES6-1A12), IL-4 (BVD4-1D11), or IFN-
(R46A2) (2 µg/ml, 100 µl/well) at 4°C overnight. After blocking with 10% FCS-PBS and washing with PBS, varying numbers of spleen cells from either naive mice or mice that had been immunized twice with KLH-DNP were added to the wells. For APCs we used T cell–depleted, mitomycin C–treated spleen cells from C57BL6/j mice (2 x 105/well). KLH or medium control was added before overnight incubation. The cells were washed away using PBS-0.1% Tween 20. Biotinylated mAbs specific for either IL-2 (JES6-5H4), IL-4 (BVD6.24G2), or IFN-
(XMG1.2) were added. HRP-labeled avidin (PharMingen) and its substrate 3-amino-9-ethylcarbazole were used to visualize the cytokine-producing spots.
Induction of CD40L on CD4 T Cells from Different Strains of Mice.
We used a previously published protocol (22) to detect maximal level of induced CD40L on CD4 T cells. In brief, spleen cells (3 x 106/ml) from primed mice were stimulated with anti-CD3 mAb for 4 h in the presence of PE-labeled anti-CD40L mAb MR-1 (1µg/ml, PharMingen). The unbound mAb was washed away, while the CD4 T cells were marked using FITC-labeled anti-CD4 mAb (PharMingen). To verify the specificity of the PE-MR1 staining, we used 100-fold excess of unlabeled MR-1 or control HB224 mAb to block the staining.
| Results and Discussion |
|---|
|
|
|---|
|
|
|
producers. Although CD28-deficiency caused a threefold reduction in the number of IL-2–producing cells, it did not significantly affect the number of IL-4 and IFN-
producers. Targeted mutation of HSA had no significant effect on the number of cytokine-producing cells. Given the critical function of cytokine-producing cells in Ig class switches, the reduction of the cytokine producers is likely to be responsible for the lack of Ig class switches in mice deficient for both HSA and CD28.
|
How does repeated antigen stimulation bypass the requirement for costimulation by CD28? We have demonstrated that in the absence of CD28–B7 interaction, induction of memory CTL and elicitation of effector from memory cells are not significantly affected, whereas induction of effector from naive T cells is abrogated (12). If the conclusion is also applicable to CD4 T cell activation, this suggests that the CD28-independent helper effectors are not directly induced from naive T cells; rather, they are elicited from memory cells induced by a HSA-dependent mechanism. This requirement for restimulation would explain the need for persistent antigenic stimulation.
HSA- and CD28-mediated costimulatory pathways appear redundant in the sense that, for some antigens, each can induce Ig class switches in the absence of the other. However, the immunological mechanism for helper induction by the two pathways can be distinct. An important difference lies in their ability to induce germinal center formation: although costimulation by CD28 is necessary for induction of germinal center (2), that by HSA is neither necessary nor sufficient (data not shown). Given the general requirement of germinal center for Ig hypermutation and affinity maturation (29), it is unlikely that T cells costimulated by HSA can promote Ig hypermutation. Although this may potentially limit the biological function of HSA-induced T helper cells, it should be noted that a recent study by Kalinke et al. has demonstrated that high-affinity neutralizing IgG antibodies against VSV can be produced without hypermutations (30).
| Acknowledgments |
|---|
This study was supported by National Institutes of Health grant AI-32981.
Submitted: 15 January 1998
Revised: 29 January 1998
| References |
|---|
|
|
|---|
1 Mueller DL, Jenkins MK & Schwartz RH. Clonal expansion vs functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen occupancy, Annu Rev Immunol, 1989, 7, 445–480.[Medline]
2 Ferguson SE, Han S, Kelsoe G & Thompson CB. CD28 is required for germinal center formation, J Immunol, 1996, 156, 4576–4581.[Abstract]
3 Ronchese F, Hausmann B, Hubele S & Lane P. Mice transgenic for a soluble form of murine CTLA-4 show enhanced expansion of antigen-specific CD4+T cells and defective antibody production in vivo, J Exp Med, 1994, 179, 809–817.
4 Gause WC, Chen SJ, Greenwald RJ, Halvorson MJ, Lu P, Xhou XD, Morris SC, Lee KP, June CH, Finkelman FD et al.. CD28-dependence of T cell differentiation of IL-4 production varies with particular type 2 immune response, J Immunol, 1997, 158, 4082–4087.[Abstract]
5 Linsley PS, Clark EA & Ledbetter JA. The T cell antigen, CD28, mediates adhesion with B cells by interacting with the activation antigen B7, Proc Natl Acad Sci USA, 1990, 87, 5031–5035.
6 Shahinian A, Pfeffer K, Lee K, Kundig KP, Kishihara TM, Wakham A, Kawai K, Ohashi PS, Thompson CB & Mak TW. Differential T cell costimulatory requirements in CD28-deficient mice, Science, 1993, 261, 609–612.
7 Zimmermann C, Seiler P, Lane P & Zinkernagel RM. Anti-viral immune response in CTLA4-transgenic mice, J Virol, 1997, 71, 1802–1807.[Abstract]
8 Liu Y, Jones B, Sullivan K, Aruffo A, Linsley PS & Janeway CA Jr. The heat-stable antigen is a costimulatory molecule for CD4 T cells, J Exp Med, 1992, 175, 437–445.
9 Liu Y, Jones B, Brady W, Janeway CA Jr & Linsley PS. Costimulation for CD4 T cell growth: Co-operation of B7 and the heat-stable antigen, Eur J Immunol, 1992, 22, 2855–2859.[Medline]
10 Enk A & Katz S. Heat-stable antigen is an important costimulatory molecule on epidermal Langerhans' cells, J Immunol, 1994, 152, 3264–3270.[Abstract]
11 De Bruijn MLH, Peterson PA & Jackson MR. Induction of heat-stable antigen expression by phagocytosis is involved in in vitroactivation of unprimed cytotoxic T lymphocytes by macrophages, J Immunol, 1996, 156, 2686–2692.[Abstract]
12 Liu Y, Wenger R, Zhou M & Nielsen PJ. Distinct costimulatory molecules are required for the induction of effector and memory cytotoxic T cell responses, J Exp Med, 1997, 185, 251–262.
13 Wang Y-C, Zhu L, McHugh R, Sell KW & Selvaraj P. Expression of heat-stable antigen on tumor cells provides co-stimulation for tumor-specific T cell proliferation and cytotoxicity in mice, Eur J Immunol, 1995, 25, 1163–1167.[Medline]
14 Reiser H & Benacerraf B. Costimulatory signal provided by a B lymphoid cell line and its Ia-negative variant, Proc Natl Acad Sci USA, 1989, 86, 10069–10073.
15 Li Y, Hellstrom KE, Newby SA & Chen L. Costimulation and B7-1 induces immunity to poorly immunogenic tumors, J Exp Med, 1996, 183, 639–644.
16 Guo Y, Wu Y, Shinde S & Liu Y. Identification of a CD40 ligand–induced costimulatory molecule as CD44H, J Exp Med, 1996, 184, 955–961.
17 Dubey C, Croft M & Swain S. Costimulatory requirement of naive CD4 T cells: ICAM-1 or B7-1 can costimulate naive CD4 T cell activation, but both are required for optimal responses, J Immunol, 1995, 155, 45–57.[Abstract]
18 Shinde S, Wu Y, Guo Y, Xu J, Grewal IS, Flavell RA & Liu Y. CD40L is important for induction of, but not response to, costimulatory activity: ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L, J Immunol, 1996, 157, 2764–2768.[Abstract]
19 DeBenedette MA, Chu NR, Pollk KE, Hurtodo J, Wade WF, Kwon BS & Watts TH. Role of 4-1BB ligand in costimulation of T lymphocyte growth and its upregulation on M12 B lymphoma by cAMP, J Exp Med, 1995, 181, 985–992.
20 Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellstrom KE, Mittler RS & Chen L. Monoclonal antibodies against 4-1BB T cell activation molecule eradicate established tumors, Nat Med, 1997, 3, 682–685.[Medline]
21 Nielsen PJ, Lorenz B, Müller AM, Wenger RH, Brombacher F, Simon M, von der Weid T, Langhorne WJ, Mossmann H & Köhler G. Altered erythrocytes and a leaky block in B-cell development in CD24/HSA-deficient mice, Blood, 1997, 89, 1058–1067.
22 Wu Y, Guo Y, Janeway CA Jr & Liu Y. Signalling by a new anti–Thy-1 monoclonal antibody interfere with B7-2–mediated costimulation for T cell growth, Cell Immunol, 1995, 165, 266–277.[Medline]
23 Foy TM, Aruffo A, Bajorath J, Buhlmann J & Noelle RJ. Immune regulation by CD40 and its ligand, Annu Rev Immunol, 1996, 14, 591–618.[Medline]
24 Mosmann TR & Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties, Annu Rev Immunol, 1989, 7, 145–173.[Medline]
25 Finkelman FD, Holmes J, Katona IM, Urban JF Jr, Beckmann MP, Park LS, Schooley KA, Coffman RL, Mosmann TR & Paul WE. Lymphokine control of in vivo immunoglobulin isotype selection, Annu Rev Immunol, 1990, 8, 303–333.[Medline]
26 Ihle J, Witthuhn BA, Quelle FW, Yamamoto K & Silvennoinen O. Signalling through the hematopoietic cytokine receptors, Annu Rev Immunol, 1995, 13, 369–398.[Medline]
27 Ding L, Green JM, Thompson CB & Shevach EM. B7/CD28-dependent and independent induction of CD40 ligand expression, J Immunol, 1995, 155, 5124–5132.[Abstract]
28 Kündig M, Shahinian A, Kawai K, Mittrücker H-W, Sebzda E, Bachmann MF, Mak TW & Ohashi PS. Duration of TCR stimulation determines costimulatory requirement of T cells, Immunity, 1996, 5, 41–52.[Medline]
29 MacLennan ICM. Germinal centers, Annu Rev Immunol, 1994, 12, 117–139.[Medline]
30 Kalinke U, Bucher EM, Ernst B, Oxenius A, Roost HP, Geley S, Kofler R, Zinkernagel RM & Hengartner H. The role of somatic mutation in the generation of protective humoral immune response against vesicular stomatitis virus, Immunity, 1996, 5, 639–652.[Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|